Novel target and pathways: driving new approaches to tackling the TME and resistance to I-O therapeutics

IMMUNO-ONCOLOGY INSIGHTS

Novel target and pathways: driving new approaches to tackling the TME and resistance to I-O therapeutics

April 2022
Novel target and pathways: driving new approaches to tackling the TME and resistance to I-O therapeutics

Foreword

Forging new paths in immuno-oncology

Forging new paths in immuno-oncology

Roisin McGuigan, Mihriban Tuna
7 April 2022
Read

Expert Insight

Kick-starting tumor specific T cell priming & targeting the tumor microenvironment using CD40 targeting bispecific antibodies

Kick-starting tumor specific T cell priming & targeting the tumor microenvironment using CD40 targeting bispecific antibodies

Karin Hägerbrand, Peter Ellmark
11 April 2022
Read

Commentary

Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?

Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?

Ning Wang
27 March 2022
Read

Interview

Driving disruption in the solid tumor space: is it time to shift paradigms and develop novel immuno-oncology strategies?

Driving disruption in the solid tumor space: is it time to shift paradigms and develop novel immuno-oncology strategies?

Edward Patz
6 April 2022
Read
Promise & challenges in discovering cellular immunotherapies &T cell engagers for solid tumor indications

Promise & challenges in discovering cellular immunotherapies &T cell engagers for solid tumor indications

Pallavur Sivakumar
27 March 2022
Read

Viewpoint

The end of an era of cancer drug discovery: life without new drug targets

The end of an era of cancer drug discovery: life without new drug targets

Armen Mardiros, Alexander Kamb
12 April 2022
Read